Ryan Cohlhepp Sells 536 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 536 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $29.00, for a total transaction of $15,544.00. Following the transaction, the chief operating officer owned 181,641 shares in the company, valued at $5,267,589. The trade was a 0.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.29, for a total transaction of $253,625.00.
• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.01, for a total transaction of $287,625.00.

Bicara Therapeutics Stock Down 2.6%

NASDAQ:BCAX traded down $0.77 during trading hours on Friday, hitting $28.91. 584,437 shares of the stock were exchanged, compared to its average volume of 1,011,479. The company’s 50 day moving average is $23.43 and its two-hundred day moving average is $20.10. Bicara Therapeutics Inc. has a twelve month low of $9.47 and a twelve month high of $30.99. The company has a market capitalization of $1.90 billion, a P/E ratio of -10.40 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, equities research analysts expect that Bicara Therapeutics Inc. will post -3.48 EPS for the current year.

Hedge Funds Weigh In On Bicara Therapeutics

Several institutional investors have recently modified their holdings of the stock. Cantor Fitzgerald L. P. bought a new position in Bicara Therapeutics during the third quarter worth about $1,579,000. UBS Group AG increased its holdings in shares of Bicara Therapeutics by 97.4% in the fourth quarter. UBS Group AG now owns 192,191 shares of the company’s stock worth $3,235,000 after acquiring an additional 94,829 shares in the last quarter. Cinctive Capital Management LP bought a new stake in shares of Bicara Therapeutics in the third quarter worth about $661,000. Walleye Capital LLC acquired a new stake in shares of Bicara Therapeutics during the first quarter worth about $2,148,000. Finally, Candriam S.C.A. acquired a new stake in shares of Bicara Therapeutics during the first quarter worth about $4,750,000.

Wall Street Analysts Forecast Growth

BCAX has been the subject of several recent research reports. Morgan Stanley boosted their price objective on Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. Wells Fargo & Company boosted their price target on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 31st. Guggenheim started coverage on shares of Bicara Therapeutics in a report on Monday, May 11th. They issued a “buy” rating and a $42.00 price objective on the stock. Finally, The Goldman Sachs Group raised their price objective on shares of Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.27.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.